Barclays raised the firm’s price target on Johnson & Johnson to $234 from $217 and keeps an Equal Weight rating on the shares. The firm says its analysis confirms the company’s “strong” 23% U.S. pharma growth excluding Stelara in Q4 is continuing in Q1, led by strong growth in both its established and emerging U.S. franchises. Barclays upped Johnson & Johnson’s estimates as a result.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Icotyde label upside surprise for Protagonist, says H.C. Wainwright
- Trump Trade: President issues short-term waiver of Jones Act
- Trump claims TrumpRx website offers lowest prices, review says not so, NYT says
- Protagonist announces Johnson & Johnson received approval for ICOTYDE
- Johnson & Johnson announces U.S. FDA approved Icotyde